Navigation Links
Sanofi-aventis Announces Second Quarter 2009 Results
Date:7/29/2009

in the Other Countries region (up 31.8% at euro 85 million). First-half net sales of the product were up 6.9% at euro 1,542 million.

No biosimilar of Lovenox((R)) has been approved in the United States to date.

Taxotere((R)) achieved second-quarter growth of 10.7% to euro 584 million, driven by its use in adjuvant breast cancer treatment and in prostate cancer. Growth was good across all three geographic regions, at 10.7% in Europe (to euro 239 million), 9.6% in the United States (to euro 228 million) and 12.7% in the Other Countries region (to euro 117 million). In Japan, the product continued its advance with net sales up 13.4% at euro 34 million, boosted in particular by the prostate cancer indication approved in the second half of 2008.

In June 2009, the Committee for Medicinal Products for Human Use (CHMP) of the EMEA issued a positive opinion on Roche's Avastin((R)) in combination with Taxotere((R)) as a first line treatment for women with metastatic breast cancer, based on the results of the AVADO study. First-half net sales of Taxotere((R)) were up 9.5% at euro 1,118 million.

Eloxatin((R)), the leading cytotoxic agent in the colorectal cancer market as an adjuvant and as a first-line treatment in the metastatic phase, achieved second-quarter growth of 10.0% in the United States to euro 282 million. Total net sales of the product reflect ongoing competition from generics in Europe, and were down 4.3% at euro 353 million. First-half net sales of Eloxatin((R)) were down 5.7% at euro 697 million. In June 2009, the U.S. District Court for the District of New Jersey ruled against sanofi-aventis by granting summary judgment motions brought by certain generics companies in the U.S. Eloxatin((R)) patent litigation. Sanofi-aventis has appealed this decision, and the Appellate Court issued an order temporarily staying the district court's judgment. As of th
'/>"/>

SOURCE sanofi-aventis
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27

Related biology technology :

1. Sanofi-aventis Announces Settlement of Average Wholesale Price Civil Suits With the U.S. Department of Justice Relating to Anzemet(R)
2. Shareholder Class Action Filed Against Sanofi-Aventis by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
3. Sanofi-aventis SoloSTAR(R) Insulin Pen for Lantus and Apidra Receives the Prestigious GOOD DESIGN Award
4. ThalesNano Inc. and sanofi-aventis R&D Collaborate on Continuous Process Chemistry in Order to Dramatically Reduce Drug Realization Time
5. RainDance Technologies Signs a Collaboration Agreement with sanofi-aventis and Louis Pasteur University to Launch dScreen Consortium within ALSACE BIOVALLEY cluster
6. AEterna Zentaris and Sanofi-Aventis Sign a Development, Commercialization and Licensing Agreement for Cetrorelix in Benign Prostatic Hyperplasia
7. BioWa Announces License of POTELLIGENT(R) Technology to sanofi-aventis
8. Sanofi-aventis U.S. to Acquire Oral Chronic Lymphocytic Leukemia Treatment
9. Sanofi-aventis U.S. Announces Settlement of Medicaid Best Price Investigation
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/27/2014)... 2014 Kalorama Information says that PCR is ... the United States and is ... researcher said the FDA,s Emergency Use Authorization (EUA) to authorize ... the detection of the Ebola virus was an indication ... assess the IVD industry and its biennial survey on ...
(Date:10/27/2014)... The report “Smart Highway Market ... Communication, Monitoring), and by Display (Variable Message Signs, ... the global market into various sub-segments with in-depth ... the drivers and restraints for this market with ... 75 market tables and 37 figures spread through ...
(Date:10/26/2014)... The report "Data Center Networking ... Equipment, WAN Optimization Appliances]: Global Advancements, Worldwide Forecasts ... center networking market into various segments with an ... also identifies the factors driving this market, various ... with the future roadmaps. , Browse 106 market ...
(Date:10/25/2014)... (PRWEB) October 23, 2014 BioProcess ... winners for the 2014 BioProcess International Awards. The ... social corporate responsibility and technology applications that will ... treatments to a global patient base. , Winners ... peers during a very entertaining and exciting awards ...
Breaking Biology Technology:Kalorama: PCR The Go-to Test in Ebola Fight 2Kalorama: PCR The Go-to Test in Ebola Fight 3Smart Highway Market by Technology, and Display Expected to Reach $27.992.0 Million by 2019- New Report by MarketsandMarkets 2Smart Highway Market by Technology, and Display Expected to Reach $27.992.0 Million by 2019- New Report by MarketsandMarkets 3Smart Highway Market by Technology, and Display Expected to Reach $27.992.0 Million by 2019- New Report by MarketsandMarkets 4Data Center Networking Market by Ethernet Switches, SAN & Routers Worth $21.85 Billion by 2018 - New Report by MarketsandMarkets 2Data Center Networking Market by Ethernet Switches, SAN & Routers Worth $21.85 Billion by 2018 - New Report by MarketsandMarkets 3Data Center Networking Market by Ethernet Switches, SAN & Routers Worth $21.85 Billion by 2018 - New Report by MarketsandMarkets 4BioProcess International Announces Winners of the 2014 BioProcess International Awards 2BioProcess International Announces Winners of the 2014 BioProcess International Awards 3BioProcess International Announces Winners of the 2014 BioProcess International Awards 4BioProcess International Announces Winners of the 2014 BioProcess International Awards 5
... BEIJING, Aug. 20 /PRNewswire-Asia-FirstCall/ -- China Medical ... leading China-based medical device,company that develops, manufactures and markets ... its unaudited financial results,for the fourth fiscal quarter ("4Q ... the first fiscal quarter ("1Q FY2009") ended June 30, ...
... , SEATTLE, Aug. 19 Cell Therapeutics, Inc. ... into an agreement to sell $30 million of shares of its Series ... in a registered offering to a single institutional investor. Each share ... holder, at any time during its existence, into approximately 628 shares of ...
... , , COLUMBIA, Md., Aug. 19 Martek Biosciences ... the results of its third quarter of fiscal 2009 on September 2, ... at 4:45 p.m. ET Martek will conduct a conference call to discuss ... call live via webcast by visiting Martek,s web site at ...
Cached Biology Technology:China Medical Technologies to Announce Unaudited Financial Results for the Fourth Fiscal Quarter and Fiscal Year ended March 31, 2009 and the First Fiscal Quarter ended June 30, 2009 on September 1, 2009 2Cell Therapeutics, Inc. Announces Institutional Investor Purchases $30 Million of Preferred Stock and Warrants 2Cell Therapeutics, Inc. Announces Institutional Investor Purchases $30 Million of Preferred Stock and Warrants 3
(Date:10/29/2014)... by the international Cancer Genomics of the Kidney ... between kidney cancer and exposure to aristolochic acid, ... published in Nature Communications , have important ... more than 140,000 people every year, and in ... CAGEKID, part of the International Cancer Genome Consortium ...
(Date:10/28/2014)... have published a paper in the Proceedings of ... details about key transitions in the evolution of plant ... mosses, ferns, trees and flowers growing deep in steamy ... the ornamental plants adorning our homes, all plant life ... "Our study generated DNA sequences from a vast number ...
(Date:10/28/2014)... be building a hybrid micro-grid which will integrate ... in the region, the hybrid micro-grid will test ... diesel, storage and power-to-gas technologies, and ensure these ... built under the new Renewable Energy Integration Demonstrator- ... located offshore at Semakau Landfill and is expected ...
Breaking Biology News(10 mins):Kidney cancer in Central Europe 2New study uses DNA sequences to look back in time at key events in plant evolution 2New study uses DNA sequences to look back in time at key events in plant evolution 3NTU to build region's first renewable energy integration demonstration micro-grid 2NTU to build region's first renewable energy integration demonstration micro-grid 3
... Mary Lee Dequeant, Ph.D., a Predoctoral Researcher at the ... Stowers Institute Investigator and an investigator with the Howard ... respectively, on a paper that identifies a network of ... of spine formation in the embryo. , ...
... identified the molecular signature of these epidermal neural crest ... conflicting scientific opinions by showing that these cells are ... Their work provides a valuable resource for future mouse ... the research from Dr. Maya Sieber-Blum's laboratory, co-authored by ...
... University researchers have identified a unique mechanism of action ... the treatment of multiple sclerosis. , The researchers report ... drug that was already known to affect the functioning ... white blood cells from the lymph nodes into the ...
Cached Biology News:Stem cells found in adult hair follicles may provide alternative to embryonic stem cells 2Novel mechanism of action of new drug for MS identified 2
MAb to Mouse MHC Class I H-2Kd...
... Agarose Gel-Digesting Preparation contains a unique β-agarose ... quantitative recovery of intact DNA and RNA ... following electrophoresis in TAE, TBE, MOPS, or ... directly in the TAE, TBE, MOPS, and ...
... Gel-Digesting Preparation contains a unique β-agarose digesting ... recovery of intact DNA and RNA from ... electrophoresis in TAE, TBE, MOPS, or phosphate ... in the TAE, TBE, MOPS, and phosphate ...
... is causing shortages in your laboratory or ... can cause unwanted distractions, problems and delays. ... your hard work and endeavour! Bring us ... up and market it internationally. We work ...
Biology Products: